2024-2025季深圳学龄儿童流感疫苗真实世界效果:检测阴性设计研究
该研究采用检测阴性设计评估深圳学龄儿童2024-2025季流感疫苗效果,纳入1669名参与者(463例病例、1206例对照)。总体调整疫苗有效性为46.36%(95%CI: 29.23-59.34%),且存在年龄、亚型、接种后时间及既往接种史差异。
要点
- 总体调整VE为46.36%(95%CI: 29.23-59.34%),主要见于低龄儿童
- 接种后14-119天有显著保护,120-239天不显著,240-299天再现
- 既往季接种无显著残余保护,连续两季接种降低当季有效性
核心结论
- 流感疫苗对深圳学龄儿童2024-2025季流感相关门诊就诊提供中等有效性,总体调整VE为46.36%(95%CI: 29.23-59.34%)。
研究设计与样本
- 采用检测阴性设计,纳入深圳学龄儿童1669名(463例实验室确诊流感病例,1206例检测阴性对照),通过问卷和实验室检测分类,用多变量逻辑回归比较接种 odds。
主要发现
- 总体调整VE为46.36%(95%CI: 29.23-59.34%),不同年龄组VE有差异,主要见于低龄儿童。
- 接种后14-119天有显著保护,120-239天不显著,240-299天夏季高峰再现保护。
- 既往季接种 alone 无显著残余保护,连续两季接种与当季有效性降低相关。
- 亚型特异性VE:A(H1N1) 43.48%(95%CI: 18.00-61.04%),A(H3N2) 34.42%(95%CI: 0.55-56.76%),B/Victoria 56.95%(95%CI: 7.68-79.93%)。
- 冬春季高峰期间VE为49.84%(95%CI: 26.90-65.59%)。
临床怎么用
- 学龄儿童接种流感疫苗可中等程度减少流感相关门诊就诊,应关注低龄儿童接种。
- 接种后保护随时间变化,需注意接种时机以覆盖流行高峰。
- 连续两季接种可能降低当季有效性,应个体化评估既往接种史。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To comprehensively evaluate the real-world effectiveness of the influenza vaccine among school-aged children across a dual-peak season, specifically examining subtype-specific protection, age variations, durability of protection over time, and the impact of repeated prior-season vaccination. METHODS: A test-negative design was used to assess vaccine effectiveness (VE) among school-aged children in Shenzhen. Based on questionnaire data and laboratory testing, patients with laboratory-confirmed influenza were classified as cases, while test-negative patients served as controls. Multivariable logistic regression was applied to compare the odds of vaccination between cases and controls. RESULTS: Among 1669 eligible participants (463 cases and 1206 test-negative controls), the overall adjusted VE against medically attended influenza was 46.36% (95% CI: 29.23-59.34%). VE differed across age groups and was mainly observed in younger children. Significant protection was observed within 14-119 days post-vaccination, became non-significant during 120-239 days, and re-emerged during the summer peak at 240-299 days. Prior-season vaccination alone provided no significant residual protection, while repeated vaccination across two consecutive seasons was associated with reduced effectiveness in the current season. Subtype-specific VE was 43.48% (95% CI: 18.00-61.04%) against influenza A(H1N1), 34.42% (95% CI: 0.55-56.76%) against influenza A(H3N2), and 56.95% (95% CI: 7.68-79.93%) against the B/Victoria lineage. During the winter-spring peak, VE was 49.84% (95% CI: 26.90-65.59%). CONCLUSIONS: Influenza vaccine provided moderate effectiveness against influenza-associated outpatient visits among school-aged children in Shenzhen during the 2024-2025 season.
引用
- Lu J, Ouyang Z, Huang F, et al. Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study. Vaccine. 2026. PMID: 42702143. doi:10.1016/j.vaccine.2026.129100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。